RCUS insider sale: 4,314 shares at $20.3175 under 10b5-1 plan

Q: What did RCUS’s President report in this Form 4?

An open-market sale of 4,314 shares of Arcus Biosciences common stock on 10/30/2025 .

Q: At what price were the RCUS shares sold?

A weighted average price of $20.3175 , with individual trades from $20.12 to $20.63 .

Q: Was the RCUS trade under a Rule 10b5-1 plan?

Yes. It was executed pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024 .

Q: How many RCUS shares does the insider hold after the sale?

Beneficial ownership is 1,087,060 shares indirectly (by trust) and 367,220 shares directly.

Q: What is the insider’s role at Arcus Biosciences (RCUS)?

The reporting person is an Officer , serving as President .

Q: What is the transaction date on the RCUS Form 4?

The transaction occurred on 10/30/2025 .

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Arcus Biosciences (RCUS): The company’s President reported an open‑market sale of 4,314 shares of common stock on 10/30/2025 at a weighted average price of $20.3175, executed under a Rule 10b5‑1 trading plan adopted on August 12, 2024.

Following the transaction, the reporting person beneficially owned 1,087,060 shares indirectly (by trust) and 367,220 shares directly. The price reflected multiple trades between $20.12 and $20.63.

Insider Trade Summary

Net Seller: 4,314 shares ($87,650)

Net Sell 2 txns

Insider Jaen Juan C.

Role President

Sold 4,314 shs ($88K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,314	$20.3175	$88K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,087,060 shares (Indirect, By Trust); Common Stock — 367,220 shares (Direct)

Footnotes (1)

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2024. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.12 to $20.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

11/03/2025 - 04:46 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jaen Juan C.

(Last)

(First)

(Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD

94545

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/30/2025		S		4,314⁽¹⁾	D	$20.3175⁽²⁾	1,087,060	I	By Trust
Common Stock								367,220	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2024.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.12 to $20.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Remarks:

	/s/ Carolyn Tang, Attorney-in-Fact	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did RCUS’s President report in this Form 4?

An open-market sale of 4,314 shares of Arcus Biosciences common stock on 10/30/2025.

At what price were the RCUS shares sold?

A weighted average price of $20.3175, with individual trades from $20.12 to $20.63.

Was the RCUS trade under a Rule 10b5-1 plan?

Yes. It was executed pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024.

How many RCUS shares does the insider hold after the sale?

Beneficial ownership is 1,087,060 shares indirectly (by trust) and 367,220 shares directly.

What is the insider’s role at Arcus Biosciences (RCUS)?

The reporting person is an Officer, serving as President.

What is the transaction date on the RCUS Form 4?

The transaction occurred on 10/30/2025.